MARKET INTELLIGENCE·Product Launch
Legend Biotech's 10% Stock Drop Signals Deeper Concerns Despite Record Carvykti Sales
Legend Biotech experienced a 10% stock drop despite partner Johnson & Johnson reporting record sales for their CAR-T therapy, Carvykti, in multiple myeloma. This market reaction, triggered by J&J's earnings call comments, signals investor concerns beyond immediate revenue. Decision-makers must scrutinize partnership communication and supply chain perceptions in advanced therapy commercialization.
90-Day Activity